Agonist-regulated alteration of the affinity of pancreatic muscarinic cholinergic receptors

• Published in: The Journal of biological chemistry Vol. 268; no. 30; pp. 22436 - 22443
• Main Authors: Doi, R, Chowdhury, P, Rayford, P.L.
• Format: Journal Article
• Language: English
• Published: Bethesda, MD Elsevier Inc 25.10.1993; American Society for Biochemistry and Molecular Biology
• Subjects: Amylases - metabolism; Animals; Binding, Competitive; Biological and medical sciences; Carbachol - pharmacology; Cell receptors; Cell structures and functions; Cholecystokinin - pharmacology; Dose-Response Relationship, Drug; Fundamental and applied biological sciences. Psychology; In Vitro Techniques; Inositol 1,4,5-Trisphosphate - metabolism; Kinetics; Male; Molecular and cellular biology; Monoamines receptors (catecholamine, serotonine, histamine, acetylcholine); Muscarinic Antagonists; N-Methylscopolamine; Pancreas - metabolism; Parasympathomimetics - metabolism; Parasympathomimetics - pharmacology; Rats; Rats, Sprague-Dawley; Receptors, Muscarinic - drug effects; Receptors, Muscarinic - metabolism; Scopolamine Derivatives - metabolism; Tetradecanoylphorbol Acetate - pharmacology; Vertebrata; Cholinergic receptor; Mammalia; Desensitization; Rat; Rodentia; Muscarinic receptor; Cholecystokinin; Pancreas; Biological receptor
• ISSN: 0021-9258; 1083-351X
• DOI: 10.1016/S0021-9258(18)41548-7

Heterologous desensitization is a term that indicates that exposure of a cell to an agonist attenuates the response of that cell to other agonists. We examined heterologous desensitization of muscarinic cholinergic receptors of pancreatic acini and characterized mechanisms that might be responsible for desensitization. Muscarinic cholinergic receptor binding was measured by using N-[3H]methscopolamine bromide ([3H]NMS). N-Methscopolamine bromide (NMS), a receptor antagonist, bound to a single class of receptors with an affinity of 0.22 +/- 0.04 nM and a capacity of 61.5 +/- 5.1 fmol/mg of protein. These parameters of NMS binding sites were not altered by an addition of cholecystokinin (CCK) octapeptide, CCK-JMV-180, vasoactive intestinal peptide, 8-bromo-cAMP, 4-bromo-A23187, thapsigargin, or 12-O-tetradecanoylphorbol-13-acetate (TPA). Analysis of competitive inhibition curve of [3H] NMS binding by carbachol showed apparently two classes of carbachol binding sites with high affinity (38.6%) and low affinity (61.4%). Simultaneous incubation of carbachol with CCK or TPA increased the relative affinity of [3H]NMS binding, and the competitive inhibition curves showed a single class of carbachol binding site. L-364,718 blocked the effect of CCK, and staurosporine blocked the effects of TPA and partially blocked the effect of CCK. CCK-JMV-180, vasoactive intestinal peptide, 8-bromo-cAMP, 4-bromo-A23187, and thapsigargin had no effects on the competitive binding. Second, the carbachol-induced sequestration of the receptors was examined. Incubation of acini with carbachol resulted in a decrease of [3H] NMS binding sites, and the addition of CCK or TPA caused an inhibition of the carbachol-induced disappearance of [3H]NMS binding sites. Finally, studies that examined the biological response of the acinar cells showed that biphasic amylase release in response to carbachol was completely suppressed by 10 nM CCK for entire range of carbachol. Taken together, these results suggest that the effect of CCK on carbachol-induced sequestration is important for the alteration of the apparent affinity of carbachol binding sites and the biological response of acinar cells to carbachol. Further, the results suggest that another factor that induces uncoupling of receptor from effector might be involved in agonist-regulated desensitization. The results, that CCK-JMV-180 or other agonists that activate the adenylate cyclase pathway did not exert these effects of CCK, suggest that protein kinase C may be one of the key factors involved in heterologous desensitization by CCK on the carbachol binding sites and the suppression of carbachol-induced amylase release.